Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Flecainide: a new antiarrhythmic agent].

J F Leclercq, P Coumel

    Archives Des Maladies Du Coeur Et Des Vaisseaux
    |October 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Flecainide demonstrated superior efficacy compared to reference Class I antiarrhythmics for resistant atrial arrhythmias and ventricular tachycardia (VT). Careful dosage adjustment is recommended to minimize potential cardiac side effects, especially in patients with heart failure.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Transvenous cryo-ablation of the slow pathway for the treatment of atrioventricular nodal re-entrant tachycardia: a single-centre initial experience study.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2007
    Same author

    [Indications for implantable automatic ventricular defibrillators. A report from the Heart Rhythm Group of the French Society of Cardiology].

    Archives des maladies du coeur et des vaisseaux·2006
    Same author

    [Hypertension and age over 70 years are the two most important risk factors for stroke in patients with atrial fibrillation].

    Annales de cardiologie et d'angeiologie·2004
    Same author

    [Atrial vulnerability: a new protocol by bigeminy pacing].

    Annales de cardiologie et d'angeiologie·2003
    Same author

    [From provocation tests to clinical practice: invasive and non-invasive electrophysiology].

    Archives des maladies du coeur et des vaisseaux·2003
    Same author

    [Indications for implantable automatic defibrillators: critical analysis].

    Archives des maladies du coeur et des vaisseaux·2003
    Same journal

    Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

    Archives des maladies du coeur et des vaisseaux·2010
    Same journal

    A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

    Archives des maladies du coeur et des vaisseaux·2010
    Same journal

    Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

    Archives des maladies du coeur et des vaisseaux·2010
    Same journal

    Alterations in coronary circulation during aortic insufficiency in young subjects.

    Archives des maladies du coeur et des vaisseaux·2010
    Same journal

    Cardio-esophageal auscultation.

    Archives des maladies du coeur et des vaisseaux·2010
    Same journal

    Hypertensive accidents following the injection of acetylcholine.

    Archives des maladies du coeur et des vaisseaux·2010
    See all related articles

    Area of Science:

    • Cardiology
    • Clinical Pharmacology

    Background:

    • Flecainide is a Class I antiarrhythmic drug.
    • Resistant arrhythmias require effective therapeutic options.

    Purpose of the Study:

    • To evaluate the clinical efficacy and safety of flecainide in patients with various arrhythmias.
    • To compare flecainide's effectiveness against quinidine and disopyramide.

    Main Methods:

    • Clinical experience with flecainide in 44 patients across three groups.
    • Arrhythmia assessment using score tests, Holter monitoring, and provocative pacing.
    • Comparison with quinidine and disopyramide, often with concurrent amiodarone use.

    Main Results:

    • Flecainide showed equivalent results to quinidine in sensitive arrhythmias.

    Related Experiment Videos

  • Flecainide was significantly more effective than reference drugs for resistant atrial arrhythmias and VT (p<0.01 and p<0.001).
  • Good tolerance was observed, with dose-dependent neurosensory side effects in 4 cases.

    • Conclusions:

    • Flecainide is a valuable option for resistant atrial arrhythmias and VT.
    • Cardiac side effects, including mortality, were associated with high doses (>5 mg/kg/day) and severe heart failure.
    • Dosage individualization based on clinical status and serum levels may reduce complications.